Triple

T10292292
Position Surface form Disambiguated ID Type / Status
Subject human adenovirus serotype 26 E241391 entity
Predicate usedInVaccineAgainst P13821 FINISHED
Object SARS-CoV-2 E335284 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: SARS-CoV-2 | Statement: [human adenovirus serotype 26, usedInVaccineAgainst, SARS-CoV-2]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: SARS-CoV-2
Context triple: [human adenovirus serotype 26, usedInVaccineAgainst, SARS-CoV-2]
  • A. SARS-CoV-2 chosen
    SARS-CoV-2 is the novel coronavirus responsible for the global outbreak of the respiratory disease COVID-19.
  • B. Omicron variant
    The Omicron variant is a highly mutated and fast-spreading strain of the SARS-CoV-2 virus that caused major global surges in COVID-19 cases starting in late 2021.
  • C. Omicron
    Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
  • D. BNT162b2
    BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
  • E. Ad26.COV2.S
    Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: usedInVaccineAgainst
Context triple: [human adenovirus serotype 26, usedInVaccineAgainst, SARS-CoV-2]
  • A. vaccineUsed
    Indicates that a particular vaccine has been administered or applied in a given medical or experimental context.
  • B. usedAgainst chosen
    Indicates that one entity is employed, applied, or deployed in opposition to, or for the purpose of affecting, another entity.
  • C. covid19VaccineType
    Indicates the specific type or category of COVID-19 vaccine associated with an entity.
  • D. hasVaccine
    Indicates that one entity possesses, provides, or is associated with a specific vaccine in relation to another entity.
  • E. areUsedIn
    Indicates that certain entities serve as components, tools, or resources within a particular process, context, or application.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d381aaafc08190af475ef58dc16aba completed April 6, 2026, 9:49 a.m.
NER Named-entity recognition batch_69d4d2d35f048190a215493acdf1f718 completed April 7, 2026, 9:48 a.m.
NED1 Entity disambiguation (via context triple) batch_69d71d1465e88190aaa8b295df3f9c8c completed April 9, 2026, 3:29 a.m.
PD Predicate disambiguation batch_69d4d1f35e548190be3b4d92d65d2d20 completed April 7, 2026, 9:44 a.m.
Created at: April 6, 2026, 11:42 a.m.